Morgan Stanley Calling For Biogen To End The Day Flat To Slightly Up Following Eli Lilly Data Results; Says aducanumab More Potent Than solanezumab, Believes Indication Of Activity/Trends Could Keep Amyloid Debate Alive
Paul Quintaro